Published in

BioMed Central, Experimental Hematology and Oncology, 1(1), 2012

DOI: 10.1186/2162-3619-1-17

Links

Tools

Export citation

Search in Google Scholar

Long lasting complete molecular remission after suspending dasatinib treatment in chronic myeloid leukemia

Journal article published in 2012 by Klára Gadó, András Matolcsy, Judit Csomor, Dóra Kicsi, Csaba Bödör ORCID, Gyula Domján
This paper is made freely available by the publisher.
This paper is made freely available by the publisher.

Full text: Download

Green circle
Preprint: archiving allowed
Upload
Green circle
Postprint: archiving allowed
Upload
Green circle
Published version: archiving allowed
Upload
Policy details
Data provided by SHERPA/RoMEO

Abstract

Abstract Tyrosine kinase inhibitors specific for BCR-ABL, were a major breakthrough in CML therapy. Second generation tyrosine kinase inhibitors (dasatinib, nilotinib) are indicated for imatinib resistant and intolerant patients. Present guidelines recommend continuous drug dosing for maintaining remission. There is no available data concerning the optimal duration of dasatinib therapy. We report the case of an imatinib intolerant patient who succeeded a complete molecular remission with dasatinib. Dasatinib was stopped bacause of intolerance, but complete molecular remission was sustained for one year and minor molecular remission for 27 months after discontinuation of dasatinib.